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a  b  s  t  r  a  c  t
Objectives:  Erlotinib  is  an epidermal  growth  factor  receptor  tyrosine-kinase  inhibitor  (EGFR-TKI),  used
for the treatment  of non-small  cell  lung  cancer.  As the  clinical  signiﬁcance  of  KRAS  mutational  status
has  not  yet  been  clearly  determined  in this  setting,  our  aim  was  to investigate  the  efﬁcacy  of  erlotinib  in
advanced  KRAS  mutation-negative  lung adenocarcinoma  patients.
Materials  and  methods:  MOTIVATE  is  an  open-label,  multicenter,  observational  trial  with  Tarceva®
(erlotinib)  monotherapy.  Enrolled  patients  with  advanced  (stage  IIIB/IV)  KRAS  wild  type  (WT)  lung  ade-
nocarcinoma  refractory  to  one  or two courses  of  prior  chemotherapy  were  treated  with  erlotinib  at
150 mg/day.  The  primary  endpoint  was  progression-free  survival  (PFS).  Secondary  endpoints  were  overall
survival (OS)  and  best  tumor  response  rate  (RR).
Results and conclusion:  In  total, 327  patients  were  included.  Median  PFS  and  OS  were  3.3 and 14.4 months,
respectively.  Three  patients  (1.2%)  had  complete  response,  51 patients  (20.2%)  had  partial  response  and
123  patients  (48.8%)  had  SD.
Signiﬁcantly  longer  median  PFS  and  OS  were  observed  in  Eastern  Oncology  Cooperative  Group  Perfor-
mance  Status  (ECOG  PS)  0-1 patients,  as compared  to  ECOG  PS  2-3  patients.  The  longest  median  OS  (20.5
months)  was found  in  patients  with  ECOG  PS 0-1 who  received  erlotinib  as  a second-line  therapy.  There
was  no difference  in median  OS  in  cohorts  stratiﬁed  to disease  stage  and  smoking  status.  Female  patients
had  both  longer  median  PFS  and  OS. Disease  control  rate  was  70.2%.
Our results  suggest  that erlotinib  represents  a valid  treatment  option  for  patients  with  KRAS  WT  lung
adenocarcinoma  and,  moreover,  that  KRAS  mutation  analysis  could  help  to identify  clinically  relevant
subgroups  of  NSCLC  patients  that  may  beneﬁt  from  EGFR-TKI  therapy.∗ Corresponding author at: Division of Thoracic Surgery, Department of Surgery,
omprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel
8-20, A-1090 Vienna, Austria. Tel.: +43 1 40400 5644; fax: +43 1 40400 5642.
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1. Background
Although the incidence of lung cancer shows a decreasing trend
in the western world, in addition to prostate and breast can-
cers it remains one of the leading cancer types both among men
and women, and is the main cause of cancer related mortality
in the US, as well as in Europe [1,2]. Hungary ranks ﬁrst in the
world with respect to lung cancer incidence and mortality among
men  [3].
In the last decades, the incidence of adenocarcinoma histology
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n the western world, in patients with lung adenocarcinoma, KRAS
utations are the most common (18–38% of cases), followed by
utations in the epidermal growth factor receptor (EGFR) gene
5–15% of cases) [5–8]. In Hungary, the incidence of KRAS muta-
ion in lung adenocarcinoma is 29.5% (based on the analysis of
250 patients; unpublished data). Smoking status inﬂuences the
utation of these two  genes: KRAS mutation is found mainly in
mokers, whereas the mutation of EGFR gene is more frequent in
on-smokers [6,9].
Erlotinib (OSI 744, Tarceva®, Genentech (Roche), USA) is a
otent, orally administered epidermal growth factor receptor
yrosine-kinase inhibitor (EGFR-TKI), which is well tolerated and
as been proven to prolong survival, delay symptom progres-
ion and improve quality of life versus placebo in patients with
reviously treated, advanced NSCLC in a large phase III trial
BR.21) [10,11]. Moreover, erlotinib is more effective as a ﬁrst-
ine treatment than standard chemotherapy in patients with exon
9 deletions or exon 21 (L858R) substitution mutations of EGFR
12,13]. In addition to any line of treatment of locally advanced,
etastatic NSCLC patients harboring EGFR activating mutations,
rlotinib is also approved without biomarker selection in the sec-
nd and third line therapy of NSCLC, and also as a maintenance
reatment for patients with stable, locally advanced or metastatic
SCLC after four cycles of platinum-based chemotherapy [14].
EGFR mutation is associated with adenocarcinoma histol-
gy, often found in non-smokers and more frequent in females,
specially in patients of Asian origin. Thus, patients with such char-
cteristics are likely to respond better to erlotinib [15]. Moreover,
he presence of KRAS mutations seems to be mutually exclu-
ive with EGFR mutations, and is associated with the absence of
esponse to EGFR-TKIs [16–18]. It has been conﬁrmed that smok-
rs with adenocarcinoma of the lung are more likely to have KRAS
utation positive tumors compared to non-smokers [6]. Erlotinib
reatment is particularly effective in terms of survival and tumor
esponse in patients with the aforementioned clinicopathological
haracteristics. In Hungary, the drug is approved for KRAS muta-
ion negative (wild-type; WT)  lung adenocarcinomas after failure
f at least one prior chemotherapy regimen. This observational
ohort study was conducted to prospectively collect efﬁcacy data
f erlotinib in routine clinical practice, focusing on two potential
redictive factors of erlotinib treatment, adenocarcinoma histology
nd KRAS mutational status.
. Materials and methods
.1. Study design
The study ML21623 – MOTIVATE, an open-label, non-
andomized, multicenter, non-interventional trial of erlotinib
onotherapy – investigated the efﬁcacy of erlotinib in routine clin-
cal practice in Hungary. Study population included patients with
dvanced (stage IIIB/IV) KRAS mutation-negative lung adenocarci-
oma previously treated with one or two lines of standard systemic
hemotherapy. The primary endpoint was progression-free sur-
ival (PFS), secondary endpoints were overall survival (OS), and
est overall tumor response. This publication presents the ﬁnal
fﬁcacy results of the MOTIVATE trial.
.2. KRAS mutation analysis
Mutations in codons 12 and 13 of exon 2 of the KRAS gene were
nalyzed as recently described [19]. Brieﬂy, tumor-rich microscopic
rea on H&E staining had been determined by a pathologist prior
o macrodissection from the formalin ﬁxed parafﬁn-embedded tis-
ue. DNA was extracted using the MasterPureTM DNA Puriﬁcationer 86 (2014) 54–58 55
Kit (Epicentre Biotechnologies, WI)  according to the instructions of
the manufacturer. KRAS mutations were screened by a microﬂuid-
based restriction fragment detection system characterized by 5%
mutant tumor cell content sensitivity. The sense primer was a
mismatch primer, and the PCR product contained the recognition
site of BstNI or BglI restriction endonuclease in case of the WT
KRAS gene. DNA ampliﬁcations were performed with AmpliTaq
Gold (Applied Biosystems Inc., CA) and primer pairs as follows:
KRAS codon 12: 5′-GAATATAAACTTGTGGTAGTTGGACCT-3′ and
5′-GGTCCTGCACCAGTAATATG-3′ and codon 13: 5′-GAATATAA-
ACTTGTGGTAGTTGGACCT-3′ and 5′-GGTCCTGCACCAGTAATATG-
3′. The reaction mixture of reagents for samples was  prepared,
containing 2.5 l 10× PCR buffer + Mg2+, 200 M from each dNTP,
1.00 pM/reaction of each primer, 0.8 U of AmpliTaq Gold DNA poly-
merase per reaction. Both reactions went through 38 cycles of
denaturation at 95 ◦C for 1 min, primer annealing at 55 ◦C for 1 min
and chain elongation at 72 ◦C for 2 min. The ampliﬁed products
were digested with 80 U BstNI (New England BioLabs, MA)  at codon
12 and 80 U BglI at codon 13. Enzymatic digestions were performed
at 60 ◦C (codon 12) and 37 ◦C (codon 13) for 4 h in a total volume
of 30 L. The digested PCR products were analyzed by microﬂuid
based Experion gel electrophoresis system (ExperionTM DNA 1 K
Analysis Kit; Bio-Rad Laboratories, CA). Density ratio of the mutated
band to the WT  one was calculated and samples containing >5%
of the non-WT band were considered mutation positive due to
the sensitivity threshold. Base-pair substitutions in mutant sam-
ples were veriﬁed and determined by sequencing on the ABI 3130
Genetic Analyzer System (Life Technologies, Carlsbad, CA) with the
BigDye® Terminator v1.1 Kit.
2.3. Eligibility criteria
Patients above the age of 18 years with histologically or
cytologically documented inoperable, locally advanced, recurrent
or metastatic (stage IIIB/IV – according to the 6th Edition of
the UICC-AJCC TNM Classiﬁcation) NSCLC were included in the
study. Erlotinib therapy was  administered according to the Sum-
mary of Product Characteristics (SPC) of Tarceva and the present
Hungarian reimbursement criteria (i.e. KRAS WT lung adenocarci-
noma patients who have received at least one course of standard
chemotherapy). Exclusion criteria were also in accordance with the
SPC. All patients provided written informed consent, and the proto-
col was approved by the Scientiﬁc and Research Ethics Committee
of the Medical Research Council (No.: 882-0/2010-1018EKU) and
Ethics and Scientiﬁc Committees of participating centers.
2.4. Study treatment
Patients received erlotinib 150 mg/day orally until disease pro-
gression or unacceptable toxicity. As this was  an observational trial,
dose modiﬁcation of erlotinib and any additional treatment or con-
comitant medication was at the discretion of the investigators.
Response grading (by using CT, MRI, X-ray and US) was  evaluated
by two  independent expert investigators in every two  month as
per institutional standard of care. The protocol did not require the
conﬁrmation of complete or partial response.
2.5. Statistical analysis
Descriptive statistical methods were used for analyzing efﬁcacy
data. Kaplan–Meier curves were generated to show PFS and OS.
Differences between groups were calculated with Log Rank test.
PFS was deﬁned as the time from the start of administration of
erlotinib to the ﬁrst documented progression or death. For patients
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Table  1
Baseline demographic and clinical characteristics.
Characteristic n (%)
Total number of patients 327




Ethnic origin Caucasian/white 327 (100.0)
ECOG PS
0 118 (36.1)
1  169 (51.7)
2  36 (11.0)
3  4 (1.2)
Stage
Stage IIIb 101 (30.9)
Stage IV 226 (69.1)
Prior
chemotherapy
Erlotinib second-line 214 (65.4)
Erlotinib third-line 113 (34.6)
Smoking status
Never smoker 104 (31.8)


































iCurrent smoker 95 (29.1)
COG = European Cooperative Oncology Group. PS = Performance Status.
here these time points were unavailable, the date of last visit or
ast contact was the censored time point.
. Results
.1. Patient characteristics
From 27 participating centers, 327 patients with KRAS WT lung
denocarcinoma were enrolled in the study. Accrual was performed
etween February 2008 and December 2010. The data cut-off date
as 15 April 2011. Baseline demographic and clinical characteris-
ics are summarized in Table 1. All 327 patients were of Caucasian
rigin. Of these, 164 (50.2%) were male and 163 (49.8%) were
emale. Median age at the time of enrollment was 60.8 years. 31.1%
nd 68.9% of the patients had stage IIIB and IV disease, respec-
ively. Approximately two-third of the patients received erlotinib
s second-line, and one-third as third-line therapy.
.2. Efﬁcacy results
Median PFS was 3.3 months (95% CI 2.93–3.67), and median OS
as 14.4 months (95% CI 9.46–19.34). Median PFS and OS were
igniﬁcantly longer in females when compared to males (3.8 [95%
I 2.85–4.75] vs. 3.2 [95% CI 2.99–3.41] months [p < 0.01] and 20.5
95% CI 10.36–30.71] vs. 9.4 months [95% CI 6.29–12.45] [p = 0.042],
espectively) (Fig. 1a).
Median OS was longer in patients receiving erlotinib second-
ine versus those who received erlotinib third-line (16.1 months
95% CI 8.93–23.33] vs. 9.3 months [95% CI 7.01–11.53]; p = 0.631)
Fig. 1b).
No difference was observed in OS when stratiﬁed to disease
tage (IIIB vs. IV) or smoking status (Fig. 1c), although in the third-
ine treated group never-smoker patients lived twice as long, as
urrent smokers (11 vs. 5.5 months), which was a signiﬁcant dif-
erence (p = 0.039).
A signiﬁcant and clinically meaningful correlation was observed
etween Eastern Oncology Cooperative Group Performance Sta-
us (ECOG PS) and survival. This difference in OS, but not in PFS,
emained strongly signiﬁcant when treatment line and ECOG PS
ere both taken into consideration (p < 0.001). The longest median
S (20.5 months [95% CI 12.67–28.39]) was observed in patients
ith ECOG PS 0-1 receiving erlotinib in second-line (Fig. 1d), and
n patients with ECOG PS 0, irrespective of the line of treatment
Fig. 1. (a) Overall survival according to gender. (b) Overall survival according to line
of  treatment. (c) Overall survival according to smoking status. (d) Overall survival
according to line of treatment and ECOG PS status.
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Table  2
PFS and OS according to different baseline characteristics.





0.02Female 3.8 (2.85–4.75) 20.5 (10.36–30.71)
Stage
IIIB  3.5 (2.75–4.19)
0.697
15.6 (9.70–21.57)
0.063IV 3.2 (2.73–3.74) 11.0 (5.48–16.46)
Smoking status
Never smoker 3.5 (1.78–5.28)
0.467
15.2 (6.12–24.28)
0.085Former smoker 3.2 (2.89–3.58) 11.9 (4.79–19.02)






1  3.1 (2.79–3.34) 10.9 (5.40–16.40)


































E3  1.7 (NA) 
a Log-rank test.
median OS: 25.7 months [95% CI 16.83–35.12]). The effect of differ-
nt baseline characteristics on erlotinib treatment is summarized
n Table 2.
Dose modiﬁcation was necessary for 48 patients, mainly
ecause of skin rash and diarrhea (Table 3). A longer median PFS
as detected for those who needed dose modiﬁcation (8.5 [95% CI
.44–11.56] vs. 3.1 [95% CI 2.97–3.30] months [p < 0.001]).
Best response data were available for 252 patients. Complete
esponse (CR) was achieved in 3 patients (1.2%), partial response
PR) was detected as best response in 51 patients (20.2%), and sta-
le disease (SD) was achieved in 123 patients (48.8%), all together
esulting in a disease control rate of 70.2%. Progressive disease (PD)
s best tumor response was reported in 75 patients (29.8%).
. Discussion
Data of two pivotal studies are available so far where erlotinib
as compared with placebo in advanced NSCLC patients. In
he BR.21 study, erlotinib led to a signiﬁcantly better response
ate, median PFS and OS than placebo in the entire previously
reated, unselected NSCLC patient population [10]. In the SATURN
tudy, erlotinib maintenance therapy for non-progressive disease
fter ﬁrst-line platinum treatment resulted in signiﬁcantly longer
edian PFS for the whole study population, and also for the EGFR
utant subgroup [20].
Analysis of the EGFR WT  subgroup of both studies showed that
rlotinib is an effective drug in this patient population in terms
f median PFS and OS compared to placebo [21]. In contrast, in
he ISEL study, geﬁtinib did not show survival beneﬁt for advanced
SCLC patients but predicted longer median OS for never-smoker
nd Asian patients. The observation that these attributes are linked
ith EGFR mutation status [22] suggests that geﬁtinib is effective
n the EGFR mutant subgroup.
The efﬁcacy of erlotinib as second- or third-line treatment in
GFR WT  NSCLC patients is still controversial. The TAILOR study
howed signiﬁcantly increased median PFS and a non-signiﬁcant
ut clinically meaningful median OS for patients treated with doc-
taxel in this patient population [23] and the DELTA study also
emonstrated a longer median PFS in the docetaxel group, which
able 3
rlotinib dose reduction.
Cause of dose reduction Patients (%) Dose reduction (%)
Skin rash 11.0 53.7
Diarrhea 4.3 20.9
Other 2.8 13.4
No  data available 2.8 11.91.9 (1.61–2.25)
however did not translate to overall survival beneﬁt [24]. These
results indicate that EGFR WT tumors are heterogeneous.
It is very important to emphasize that EGFR WT  NSCLC is het-
erogeneous and includes KRAS mutant cases, where the efﬁcacy of
erlotinib is least expected.
We performed an open-label, non-randomized, multicenter,
non-interventional trial of erlotinib monotherapy in patients with
advanced KRAS WT  lung adenocarcinoma. Our results conﬁrmed
the efﬁcacy of erlotinib with a median PFS of 3.3 months, a median
OS of 14.4 months and a disease control rate of 70.2% in this study
population.
The results of the present study are comparable to those from the
HORG trial, which compared pemetrexed with erlotinib in previ-
ously treated NSCLC patients [25]. Authors of this study found that
patients with KRAS WT  tumors treated with erlotinib had a sig-
niﬁcantly better median OS than the KRAS mutant subgroup (11.9
vs. 3.9 months; p = .001). The TITAN study compared erlotinib with
chemotherapy (pemetrexed or docetaxel) as second-line treatment
of histologically unselected advanced NSCLC patients. No differ-
ence was found between the two groups with respect to median
OS, neither for the whole population, nor for EGFR WT patients.
Nevertheless, the risk of death was lower in the erlotinib group
of the KRAS WT population (p = 0.041) [26]. The objective tumor
response rate of the erlotinib-arm in the TAILOR study was 3%
[23]. This is in contrast with the response rate of 21.4% in our
cohort. Disease control rates were 26% and 70.2% in the TAI-
LOR and in our study, respectively. These differences might be
explained by the different patient populations (i.e. the TAILOR
study involved KRAS mutant cases with the exclusion of EGFR
mutant ones, while our study enrolled patients with KRAS WT
tumors thus increasing the number of cases with EGFR mutant
tumors).
Earlier studies indicated that KRAS mutant NSCLC patients fail to
beneﬁt either from adjuvant chemotherapy or from EGFR inhibitors
[7,16,27–29]. Lack of EGFR mutation status of the KRAS WT  patients
represents a major limitation of our study (i.e. the presented cohort
selected for WT KRAS is composed of EGFR mutant and EGFR WT
patients, and thus it is enriched to some extent for EGFR mutant
cases). Of note, however, when this study was  initiated, EGFR status
was not regarded as a predictor of EGFR inhibitor efﬁcacy and our
central aim was to conﬁrm or rule out if KRAS mutational status
in itself (i.e. without the knowledge of patients’ EGFR status) has
a predictive role for the second or third-line erlotinib therapy of
NSCLC. Importantly, although the role of KRAS mutational analysis
in NSCLC treatment is still debated [30–32], our data suggest a pre-
dictive role of KRAS status for NSCLC patients treated with erlotinib
and, furthermore, are in line with subsequently published NCCN
NSCLC guidelines which has been incorporated the proposal that
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RAS gene sequencing could be useful for the selection of patients
s candidates for TKI therapy” [18].
As KRAS mutation is found mainly in smokers [6,33], the nega-
ive prognostic value of KRAS mutation may  be related to the poor
erformance status associated with smoking [34]. In our study,
o signiﬁcant difference was observed in survival when stratiﬁed
ccording to smoking status in the entire patient population. The
ower incidence of KRAS mutation in non-smokers and the low
umber of current smokers in the present study may  explain this
ffect.
In conclusion, the clinical value of KRAS mutation to predict
herapeutic response to EGFR-TKI treatment in NSCLC remains
mbiguous and thus EGFR mutational status analysis is currently
he preferred test in this setting [35–38]. In part because of ethical
bjections our study did not involve a cohort of patients with KRAS-
utated NSCLCs. However, the relatively high median PFS and OS
ata observed in our study do not only suggest that second or third-
ine erlotinib therapy confers signiﬁcant beneﬁt to patients with
dvanced stage KRAS WT  lung adenocarcinoma but our ﬁndings
lso support the well-known but still ambiguous concept [35–38]
hat KRAS mutation analysis might predict treatment non-response
o EGFR TKI therapy in NSCLC.
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